While the effects of prophylactic administration of IFNs at an early stage of the disease are obvious, the possibility of using type I IFNs in patients with severe COVID-19 has recently been questioned by some clinicians due to a common misconception about the possibility of an IFN-stimulated increase in inflammation and cytokine storms [39,40,41]. Here, IFNA1 is linked to COVID-19.